This section covers background and scope for tocilizumab (branded Actemra and Tyenne), a monoclonal antibody indicated across multiple immune-mediated diseases. Tocilizumab products addressed in this policy include the Actemra ACTPen, Actemra subcutaneous, Tyenne autoinjector, and Tyenne subcutaneous, and the policy applies to prior authorization requests submitted for these formulations for Fidelis Care members in North Carolina. [[0]] [[1]]
Tocilizumab is used for several rheumatologic and systemic inflammatory indications — including rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (PJIA), giant cell arteritis (GCA), and systemic sclerosis–associated interstitial lung disease (ILD‑SSc) — and coverage decisions in this policy reflect indication‑specific requirements such as documented diagnosis, prior trials of specified agents (step therapy), age limits, and specialist prescribing/consultation where noted. Continuation authorizations require documentation that the patient has experienced a response to therapy. [[1]] [[265]]
Requests for tocilizumab will be reviewed under the documented prior authorization rules in this policy, which emphasize: (1) evidence of meeting the applicable initial‑therapy entry criteria or accepted alternative conditions (for RA/PJIA step‑therapy or GCA corticosteroid prerequisite), (2) specialist involvement when required (rheumatology or pulmonology for lung disease), (3) avoidance of concurrent biologic or targeted synthetic DMARD therapy where listed as an exclusion, and (4) authorization durations consistent with the policy (commonly approve through end of plan year unless otherwise specified). Providers should submit diagnosis, prior medication history, and any required test results to support medical necessity. [[1]] [[0]]